Phase III Trial of FOLFOX plus Bevacizumab or Cediranib (AZD2171) as First-Line Treatment of Patients with Metastatic Colorectal Cancer: HORIZON III

被引：40
|
作者：
Robertson, Jane D. [1 ]
Botwood, Nick A. [1 ]
Rothenberg, Mace L. [2 ]
Schmoll, Hans-Joachim [3 ]
机构：
[1] AstraZeneca, Macclesfield, Cheshire, England
[2] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[3] Univ Halle Wittenberg, Halle, Germany
来源：
CLINICAL COLORECTAL CANCER | 2009年 / 8卷 / 01期
关键词：
5-Fluorouracil; Leucovorin; Oxaliplatin; VEGF signaling inhibitor;
D O I：
10.3816/CCC.2009.n.010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Cediranib is a highly potent and selective inhibitor of the 3 vascular endothelial growth factor receptors and has a half-life suitable for once-daily oral dosing. It is currently in phase III development for the first-line treatment of metastatic colorectal cancer. This article summarizes the clinical development program, which includes 2 global phase III studies, HORIZON II and HORIZON III, in the first-line treatment setting and a phase II study in second-line treatment (HORIZON I).
引用
收藏
页码：59 / 60
页数：2
相关论文
共 50 条
  • [1] Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: The NO16966 trial
    Tyagi, Preeta
    Grothey, Axel
    [J]. CLINICAL COLORECTAL CANCER, 2006, 6 (04) : 261 - 264
  • [2] Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer
    Vaidyanathan, Gayatri
    Groman, Adrienne
    Wilding, Gregory
    Fakih, Marwan G.
    [J]. ONCOLOGY, 2010, 79 (1-2) : 67 - 71
  • [3] Olaparib plus /- bevacizumab versus bevacizumab plus fluorouracil in patients with unresectable or metastatic colorectal cancer not progressing on first-line FOLFOX plus bevacizumab: Phase III LYNK-003 study.
    Mayo, Carlos Alberto
    Gurary, Ellen B.
    Marinello, Patricia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [4] A randomized, open-label, multicenter, phase III study of high-dose vitamin C plus FOLFOX plus /- bevacizumab versus FOLFOX plus /- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancer
    Wang, F.
    Xiao, J.
    Zhang, Y.
    Yuan, X.
    He, M.
    Fang, W.
    Zhang, Y.
    Wang, W.
    Hu, X.
    Ma, Z.
    Yao, Y.
    Zhuang, Z.
    Zhou, F.
    Ying, J.
    Yuan, Y.
    Zou, Q.
    Guo, Z.
    Wu, X.
    Jin, Y.
    Mai, Z.
    Guo, Y.
    Xu, R.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S364 - S364
  • [5] Phase III results for first-line treatment for metastatic colorectal cancer
    Kotsiliti, Eleni
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2023, 20 (02) : 65 - 65
  • [6] Phase III results for first-line treatment for metastatic colorectal cancer
    Eleni Kotsiliti
    [J]. Nature Reviews Gastroenterology & Hepatology, 2023, 20 : 65 - 65
  • [7] A phase III study of comparing FOLFOX plus /-bevacizumab with FOLFOX plus /-bevacizumab plus high-dose intravenous vitamin C as first-line therapy in patients with advanced colorectal cancer.
    Wang, Feng
    Xiao, Jian
    Zhang, Yan-Qiao
    Yuan, Xianglin
    Fang, Weijia
    Wang, Wei
    Hu, Xiaohua
    Zhuang, Zhixiang
    Zhou, Fuxiang
    Ying, Jieer
    Yuan, Ying
    Guo, Zeng-qing
    Wu, XiangYuan
    Zou, Qing-Feng
    He, Ming-ming
    Guo, Ying
    Chen, Shuang-Zhen
    Xu, Rui-hua
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] FOLFOXIRI versus FOLFOX/FOLFIRI plus Bevacizumab as first-line treatment in metastatic colorectal cancer: A systematic review and network Meta-analysis of phase III study
    Zhang, J.
    Deng, Y.
    Cai, Y.
    Hu, H.
    Xiao, J.
    Ling, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S362 - S363
  • [9] First-line treatment with bevacizumab plus capecitabine for elderly patients with metastatic colorectal cancer: BECA trial
    Feliu, J.
    Salut, A.
    Safont, M.
    Losa, F.
    Garcia, C.
    Bosch, C.
    Escudero, P.
    Lopez, R.
    Bolanos, M.
    Gonzalez-Baron, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Cediranib (AZD2171) in Patients With Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group Clinical Trial
    Alberts, Steven Robert
    Fitch, Tom R.
    Kim, George P.
    Morlan, Bruce W.
    Dakhil, Shaker R.
    Gross, Howard M.
    Nair, Suresh
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2012, 35 (04): : 329 - 333
12345